Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
08/09/26	EGP 804.43	+0.87%	3,069
07/09/26	EGP 797.52	-0.96%	477
06/09/26	EGP 805.23	+1.43%	18,745
03/09/26	EGP 793.89	+0.57%	471
02/09/26	EGP 789.39	-1.10%	6,343

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 08/09/2026			5-day change	1st Jan Change
804.43 ^EGP	+0.87%		+0.78%	+130.36%

27/08	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE
27/08	Minapharm Group Receives Funding to Advance Bundibugyo Ebolavirus Vaccine Candidate to Clinical Trials	CI

Market Cap	9.48B 186M 160M 150M 137M 256M 17.6B 257M 1.78B 688M 9B 697M 682M 28.63B	P/E 2024	14x	P/E 2025	584x
Enterprise Value	10.59B 207M 178M 168M 153M 286M 19.66B 287M 1.99B 769M 10.05B 779M 762M 31.98B	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	14.5%	Yield 2024	1.54%	Yield 2025	-

27/08	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE
27/08	Minapharm Group Receives Funding to Advance Bundibugyo Ebolavirus Vaccine Candidate to Clinical Trials	CI
17/08	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
10/06	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05/05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
30/11	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
30/11	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/09/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/09/25	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
27/07/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/07/25	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
13/06/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI
12/06/25	Minapharm Pharmaceuticals FY Colsol Net Profit EGP 161.1 Million	RE

07/07/25	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
27/03/25	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
05/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
05/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
07/03/23	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Stock

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation : MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news : MINAPHARM Pharmaceuticals

Press Releases : MINAPHARM Pharmaceuticals

Quotes and Performance

Price Extremes

Managers and Directors : MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+0.87%
1 week	+0.78%
Current month	+0.54%
1 month	+2.69%
3 months	+20.12%
6 months	+73.93%
Current year	+130.36%

1 week	780.2	815
1 month	700.2	831
Current year	320.23	831
1 year	246.01	831
3 years	145	831
5 years	101.05	831
10 years	45	831

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	19/10/2010
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Wafik El-Bardissy CHM	Chairman	-	18/10/2010
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	18/10/2010
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	+0.87%	+0.78%	+200.01%	+303.93%	185M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.14%	-2.19%	+18.70%	+66.18%	48.08B
OTSUKA HOLDINGS CO., LTD.	-0.59%	-3.73%	+37.86%	+119.39%	39.95B
ZYDUS LIFESCIENCES LIMITED	-0.12%	-0.75%	+10.62%	+82.26%	12.2B
CIPLA LIMITED	-0.56%	-2.60%	-11.31%	+10.32%	11.92B
KRKA, D. D.	-0.76%	-1.70%	+20.93%	+136.36%	9.22B
GEDEON RICHTER	-1.02%	-4.04%	+21.19%	+33.90%	7.41B
ONO PHARMACEUTICAL CO., LTD.	-1.88%	-3.60%	+36.45%	-16.49%	7.37B
GLENMARK PHARMACEUTICALS LIMITED	-0.62%	+0.07%	+16.33%	+203.57%	7.32B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.77%	-2.48%	-46.84%	+21.17%	5.17B
Average	-0.49%	-1.53%	+30.39%	+96.06%	14.88B
Weighted average by Cap.	-0.37%	-3.04%	+19.75%	+81.44%

	2024	2025
Net sales	5.66B 111M 95.41M 89.76M 81.91M 153M 10.52B 154M 1.06B 411M 5.38B 417M 408M 17.11B	6.44B 126M 108M 102M 93.1M 174M 11.96B 175M 1.21B 468M 6.11B 474M 463M 19.45B
Net income	157M 3.08M 2.65M 2.49M 2.27M 4.24M 292M 4.26M 29.49M 11.41M 149M 11.55M 11.3M 474M	40.22M 788K 677K 637K 582K 1.09M 74.69M 1.09M 7.55M 2.92M 38.17M 2.96M 2.89M 121M
Net Debt	2.6B 50.9M 43.76M 41.17M 37.57M 70.11M 4.83B 70.48M 488M 189M 2.47B 191M 187M 7.85B	1.11B 21.75M 18.7M 17.59M 16.05M 29.96M 2.06B 30.11M 208M 80.63M 1.05B 81.66M 79.88M 3.35B